Loading stock data…
Puma Biotechnology Inc (PBYI)
$9.39-0.16 (-1.68%)
Market ClosedLast close Sep 8
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Puma Biotechnology, Inc. in the Healthcare sector is trading at $9.39 with a market capitalization of $485M. The stock is currently near its 52-week high of $9.74, remaining 32.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $56.50M↑ | $44.81M↓ | $75.45M↑ | $54.48M↑ | $52.44M |
| Gross Profit | $44.03M↑ | $34.39M↓ | $52.33M↑ | $42.30M↑ | $40.13M |
| Operating Income | $7.58M↑ | -$3.83M↓ | $17.11M↑ | $9.57M↑ | $6.64M |
| Net Income | $8.19M↑ | -$3.75M↓ | $13.44M↑ | $8.84M↑ | $5.86M |
Peer Comparison
JNJUNHPFE
Fundamentals
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$484.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.41
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.97%
Volume
Today's trading volume
365,402
Recent News
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
NERLYNX demand surged 12% year over year as Puma raised full-year guidance.
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary
Moby summary of Puma Biotechnology, Inc.'s Q2 2026 earnings call
Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $